West China Hospital Oncology: Tumor-Specific Teams

Why tumour-specific departments change the question you ask

The official abdominal oncology page traces the hospital's oncology department to 1960, a center to 1996 and the abdominal division to a 2007 reorganization. It describes oncology within a general teaching hospital, not a separate cancer hospital founded in 1960. The clinical organization now includes distinct abdominal, head-neck and thoracic directions alongside disease-focused and biotherapy work.

This changes the first question an international patient should ask. Instead of "can West China Hospital treat cancer?", the useful question is "which department's documented scope covers my confirmed diagnosis, and what does that department require before it can give an opinion?" A pathology report naming the tumour type, a staging summary and the specific clinical question are more useful than a large unsorted file. The hospital, not a coordinator, decides whether a case fits a team's work.

The 2023 Fudan national specialty reputation list placed the hospital's oncology specialty at position 8. That is a dated historical reference to the specialty as a whole. It does not rank the abdominal, head and neck or thoracic departments against each other, does not rank individual clinicians, and should not be read as a current 2026 standing.

Abdominal oncology: digestive, urinary and gynaecological tumours

The abdominal oncology department describes work across digestive tract tumours, genitourinary tumours and gynaecological tumours. Its page sets out a model in which medical oncology, radiation oncology and interventional oncology contribute to multidisciplinary discussion. For a patient, that structure suggests a practical question: when several treatment modalities are plausible, who assembles the combined view, and which records does that discussion need?

The department also frames its work around biomarker-oriented questions. That phrase is worth taking literally rather than as a promise. A patient arriving with an existing molecular report should ask whether the reported markers are relevant to the tumour type under discussion, whether the testing was done on adequate tissue, and whether the team would want the original pathology material reviewed. These are questions for the treating clinicians; the answers depend on the individual case.

Research activity is documented alongside clinical work. A 2025 laboratory on the abdominal tumour immune microenvironment is listed, and the department records a 2018 gold award in a quality improvement competition and a 2014 Sichuan pain standardisation ward designation. These are institutional facts about the department's activities and recognition, not evidence that any particular patient will receive a particular treatment or outcome.

Head and neck oncology: named contributors and their territories

The head and neck oncology department names several academic contributors with distinct areas. Liu Lei and Chen Nianyong are identified with head and neck and nasopharyngeal cancer work. Zou Liqun is associated with lymphoma, Jiang Yu with melanoma and soft tissue tumours, and Wang Feng with central nervous system tumours. The department also describes collaboration on breast radiation and psycho-oncology.

These names provide an academic map rather than confirmation of a personal appointment. The head-neck program covers more than its title alone suggests: lymphoma, melanoma and soft-tissue disease, central nervous system tumors and breast-radiation collaboration have distinct contributors. Ask which clinical group would assess the established diagnosis and what the proposed review would address.

Its guideline contributions and multidisciplinary work are relevant when an enquiry crosses treatment disciplines. A patient with an existing plan can ask which part of that plan would be reviewed and how the opinion would be coordinated with other specialties. The program's range does not establish that the same approach or named clinician would be used for every case.

Thoracic oncology and the lung cancer centre

The thoracic oncology department describes lung, oesophageal and mediastinal malignancies, with medical and radiation oncologists working alongside respiratory medicine, thoracic surgery, pathology, imaging and precision medicine in multidisciplinary discussion. Its research description includes non-small cell and small cell lung cancer questions around radiation, immune response and cellular translational work, and it lists supportive care in pain, nutrition and psychology. The department page records a 2007 site-based reorganisation.

A separate lung cancer centre page, whose top overview was updated in September 2026, describes a multidisciplinary centre founded in July 2014 with surgical, medical, radiation, respiratory, rehabilitation and nutrition or traditional medicine input. It records national science and technology progress second prizes and Sichuan first prizes without specifying years or projects, and describes research using clinical databases and a biobank, molecular classification, screening, early diagnosis and follow-up.

The lung center's research interests include clinical databases, a tissue biobank, molecular classification, screening and early diagnosis, and follow-up. This disease-focused structure sits alongside the broader thoracic oncology department. For an enquiry, clarify whether the question concerns an established lung diagnosis, an earlier treatment proposal or a need for multidisciplinary assessment, then ask which service would review it.

Biotherapy research and the distinction between laboratory and clinic

Wei Yuquan's official biography identifies him as a Chinese Academy of Sciences academician with leadership roles at the clinical tumour centre and the national biotherapy laboratory. His research is described in terms of the tumour microenvironment, immune regulation, angiogenesis, drug development and translational platforms, and he is listed as a co-editor of Signal Transduction and Targeted Therapy.

That profile is a research and institutional description. It does not mean that novel cell therapy, gene therapy or an investigational drug is routinely available to an overseas patient, and it does not establish access to any clinical trial. A patient who has read about a specific experimental approach should ask the treating team whether any relevant study is open, whether the patient's tumour type and prior treatment history fit its criteria, and who makes that determination. Eligibility review is not enrolment.

The same discipline applies to the department's conference activity. A September 2024 report describes presentations to ASCO, ENETS, ESMO and ASTRO covering perioperative rectal cancer treatment questions, early-phase bispecific antibody research in gastric and gastro-oesophageal tumours, and neuroendocrine research. Conference presentations are scientific communication, not awards, not a new standard of care, and not evidence that a named regimen is appropriate for a particular patient.

Named roles, honours and what they do not tell you

Several roles appear in the official record with different degrees of precision. Bi Feng is described as professor, chief physician and doctoral mentor, leader of the medical oncology discipline and of a molecular targeted research laboratory, and a Sichuan health authority chief expert in medical oncology. His clinical and basic work is described around digestive tumours, including stomach, colorectal, liver, biliary and pancreatic disease. His earlier chemotherapy and abdominal department posts from 2006 are history, not a statement of every current role.

Cao Dan is recorded as abdominal department chief in the September 2024 conference report, and that report also names Bi Feng as medical oncology discipline head and a National Distinguished Young Scholar, and Wang Xin as abdominal and radiotherapy deputy. These are dated descriptions from a specific document. They should not be generalised into a claim that every clinical chief at the hospital holds the role a reader might assume.

The thoracic department records a 2024 multidisciplinary-clinic collective Second Prize and a 2025 Sichuan University nursing-team recognition. Abdominal oncology separately records its quality-improvement award and pain-standardization ward designation. These concern different departments and activities. They provide context about service development, while an individual assessment must address the patient's own diagnosis and unresolved treatment question.

Practical decisions before you approach a tumour-specific team

State the tumor diagnosis used by the current clinicians, previous treatment and the decision on which another opinion is sought. Ask which tumor-specific group would review it, which existing reports or pathology information should be supplied and how a multidisciplinary opinion would be communicated. Confirm the proposed assessment and acceptance before arranging travel; urgent deterioration needs local care.

ChinaSpecialistCare can help organise an oncology enquiry, prepare records and coordinate visit arrangements after hospital acceptance. We are independent of the hospital and cannot guarantee a named clinician, treatment or trial place. A brief initial enquiry is free and does not require purchasing an optional proxy consultation.

Cancer care in China for international patients

Sources & scope of this guide

References and official service information relevant to this guide.

This is general planning information and has not been individually reviewed by a doctor. Medical decisions and personal treatment advice come from your treating clinicians.